Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.
1. STOCK NEWS:
- Nuvei (NVEI) will acquire Paya Holdings (PAYA) for $9.75 per share in cash, or $1.3B [more]
- AstraZeneca (AZN) will acquire CinCor Pharma (CINC) for at least $1.3B [more]
- Ipsey (IPSEY) will acquire Albireo (ALBO) for initial estimated aggregate consideration of $952M plus one contingent value right [more]
- Duck Creek Technologies (DCT) agreed to be acquired by Vista Equity Partners for $2.6B [more]
- Lululemon (LULU) narrowed its Q4 earnings guidance and raised its Q4 revenue outlook [more]
2. WALL STREET CALLS:
- Zillow Group (Z, ZG) upgraded to Buy from Underperform at BofA [more]
- MasterCard (MA) and Visa (V) upgraded to Overweight from Sector Weight at KeyBanc [more]
- Uber (UBER) upgraded to Overweight from Neutral at Piper Sandler and assumed with a Buy at Jefferies [more]
- DoorDash (DASH) downgraded to Underweight from Neutral at Piper Sandler and initiated with an Underperform at Jefferies [more]
- GoDaddy (GDDY) downgraded to Hold from Buy at Jefferies [more]
3. AROUND THE WEB:
- Comcast's (CMCSA) NBCUniversal is expected to commence layoffs, Insider reports [more]
- Credit Suisse (CS) nears deal to buy Michael Klein's advisory firm, Bloomberg reports [more]
- Moderna (MRNA) is considering a commercial price for its COVID-19 vaccine similar to Pfizer's (PFE), WSJ reports [more]
- Disney (DIS) CEO Bob Iger told employees to return to the office four days a week, CNBC reports [more]
- Pete Stern, a top subscriptions executive, is leaving Apple (AAPL), Insider says [more]
4. MOVERS:
- Amryt Pharma (AMYT) rises in New York after entering a definitive agreement to be acquired by Chiesi Farmaceutici [more]
- Revance (RVNC) higher after announcing the FDA has accepted for review a supplemental Biologics License Application for Daxxify [more]
- CureVac (CVAC) gains after Jefferies upgraded the shares to Buy and the company appointed Alexander Zehnder as CEO [more]
- Cutera (CUTR) declines after providing FY22 revenue guidance [more]
- Cerus (CERS) lower after providing Q4 revenue guidance [more]
5. EARNINGS/GUIDANCE:
- Macy's (M) reiterated its Q4 earnings view, said sales are now expected to be at the low-end to mid-point of the previously issued range [more]
- DexCom (DXCM) provided upbeat Q4 revenue guidance [more]
- Alphatec (ATEC) reported preliminary Q4 revenue [more]
- Pfizer (PFE) sees 2025 potential non-COVID revenues, excluding business development, of roughly $52B [more]
- Sarepta (SRPT) expects to exceed FY22 guidance for net product revenues [more]
INDEXES:
The Dow fell 112.96, or 0.34%, to 33,517.65, the Nasdaq gained 66.35, or 0.63%, to 10,635.65, and the S&P 500 declined 2.99, or 0.077%, to 3,892.09.